KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Revenue: 2009-2025

Historic Revenue for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to $187.8 million.

  • Neogenomics' Revenue rose 11.90% to $187.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $709.2 million, marking a year-over-year increase of 10.10%. This contributed to the annual value of $660.6 million for FY2024, which is 11.65% up from last year.
  • Latest data reveals that Neogenomics reported Revenue of $187.8 million as of Q3 2025, which was up 3.57% from $181.3 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Revenue registered a high of $187.8 million during Q3 2025, and its lowest value of $115.5 million during Q1 2021.
  • For the 3-year period, Neogenomics' Revenue averaged around $162.7 million, with its median value being $164.5 million (2024).
  • Data for Neogenomics' Revenue shows a peak YoY increase of 39.95% (in 2021) and a maximum YoY decrease of 3.27% (in 2021) over the last 5 years.
  • Neogenomics' Revenue (Quarterly) stood at $125.7 million in 2021, then climbed by 10.32% to $138.7 million in 2022, then rose by 12.15% to $155.6 million in 2023, then grew by 10.57% to $172.0 million in 2024, then increased by 11.90% to $187.8 million in 2025.
  • Its Revenue stands at $187.8 million for Q3 2025, versus $181.3 million for Q2 2025 and $168.0 million for Q1 2025.